

* * * * * Welcome to STN International * * * * *

NEWS	1	MAR	25	New Get Prior Art Analysis Feature in CA/CAPLUS Provides an Efficient Means to Expand Search Results
NEWS	2	MAR	25	Searching Chemical Compounds with Fragmentation Codes in Derwent World Patents Index (R) Subscriber Files
NEWS	3	MAR	30	New Projects Feature Allows STNnext Users to Define and Manage Search Projects
NEWS	4	APR	4	The enhanced Derwent World Patents Index(R) is now available on STNnext
NEWS	5	APR	4	The Derwent Chemistry Resource (DCR) is now available as a standalone database on STNnext
NEWS	6	JUN	22	Claims for Four Additional Patent Authorities Added to CA/CAPLUS
NEWS	7	JUN	24	SMARTTracker SDI Option Now Supported in Derwent Files
NEWS	8	JUN	24	Expanded Claims Coverage and Enhanced HIT Displays of Claims Data in Derwent World Patents Index(R)
NEWS	9	SEP	9	Enhanced Coverage of Malaysia, Saudi Arabia, and Georgia Increases Comprehensiveness of INPADOC
NEWS	10	SEP	14	New Preference Setting for Transcript Options Helps Better Manage Transcripts, Increase Their Efficiency
NEWS	11	SEP	22	CAS STNnext Structure Editor Update Preserves Functionality, Increases Flexibility
NEWS	12	OCT	24	Links to National Patent Registers Now Available in Patent Databases on CAS STNnext
NEWS	13	NOV	7	PCTFULL Reload Provides Additional Coverage, Independent Claims and Assignee Searching Enhancements
NEWS	14	NOV	7	EPFULL Reload on STNnext Features New Independent Claims Searching Capabilities
NEWS	15	NOV	10	PS (Pharmaceutical Substances) Database Reloaded
NEWS	16	DEC	05	Expanded access to Taiwanese patent information provided by new full text database TWFULL and claims coverage in CAPLUS(SM)
NEWS	17	DEC	05	New Implementation of Derwent Drug File (DRUGU/DDFU) Makes Searching More Convenient
NEWS	18	DEC	23	New Interactive Claim Viewer in EPFULL and PCTFULL Makes Claim Analysis More Efficient
NEWS	19	DEC	30	2023 MeSH now available in MEDLINE on STNnext
NEWS	20	FEB	23	Derwent World Patents Index - Manual Code revision 2023
NEWS	21	MAR	10	MEDLINE(R) Reloaded and MeSH Thesaurus Updated for 2023 on STNnext
NEWS	22	MAR	23	Expanded Patent Authority Coverage in CA/CAPLUS Means Access to More Inventions, More Complete Patent Families
NEWS	23	MAY	12	Claim Tags Enhancement Extended to Include WO Patents
NEWS	24	MAY	15	May 2023 Update to Emtree(R) Now Available in Embase(R)

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS TRAINING Find instructor-led and self-directed training opportunities

Enter NEWS followed by the item number or name to see news on that specific topic.

For pricing information enter HELP PRICE or HELP COST at any arrow prompt.

All use of STN is subject to the provisions of the STN customer agreement. This agreement limits use to scientific research. Use for software development or design, implementation of commercial gateways, or use of CAS and STN data in the building of commercial products is prohibited and may result in loss of user privileges and other penalties.

Access the latest version of STN.

Log into STNnext with your STN login ID at <https://www.stn.org>

STNnext is updated frequently. To see the latest STNnext Release Notes, click <https://www.stn.org/help/stnnext/ReleaseNotes.htm>

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 15:30:17 ON 02 JUL 2023

=> FILE REGISTRY

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.28	0.28

FILE 'REGISTRY' ENTERED AT 15:31:02 ON 02 JUL 2023
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
COPYRIGHT (C) 2023 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 30 JUN 2023 HIGHEST RN 2939845-27-7
DICTIONARY FILE UPDATES: 30 JUN 2023 HIGHEST RN 2939845-27-7

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy>

TSCA Inventory information is current through February 2023.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/training/stn/database-specific>

=> S CTTTATTCAATGTGGC/SQSN

L1 32 CTTTATTCAATGTGGC/SQSN

=> S "PNPLA3" OR "PNPLA3" OR "Patatin-like phospholipase domain-contg. protein 3" OR "Gene PNPLA3 protein" OR "Proteins, PNPLA3" OR "Patatin-like phospholipase domain-containing protein 3" OR "Patatin-like phospholipase domain-containing proteins, PNPLA3"

14 "PNPLA3"
14 "PNPLA3"
1080 "PATATIN"
149692 "LIKE"
8785 "PHOSPHOLIPASE"
109582 "DOMAIN"
69062 "CONTG"
8613814 "PROTEIN"
144825742 "3"
1 "PATATIN-LIKE PHOSPHOLIPASE DOMAIN-CONTG. PROTEIN 3"
("PATATIN"(W)"LIKE"(W)"PHOSPHOLIPASE"(W)"DOMAIN"(W)"CONTG"(W)"PROTEIN"(W)"3")
6108128 "GENE"
14 "PNPLA3"
8613814 "PROTEIN"
1 "GENE PNPLA3 PROTEIN"
("GENE"(W)"PNPLA3"(W)"PROTEIN")
5477 "PROTEINS"
14 "PNPLA3"
1 "PROTEINS, PNPLA3"
("PROTEINS"(W)"PNPLA3")
1080 "PATATIN"
149692 "LIKE"
8785 "PHOSPHOLIPASE"

```

109582 "DOMAIN"
998416 "CONTAINING"
8613814 "PROTEIN"
144825742 "3"
1 "PATATIN-LIKE PHOSPHOLIPASE DOMAIN-CONTAINING PROTEIN 3"
  ("PATATIN"(W)"LIKE"(W)"PHOSPHOLIPASE"(W)"DOMAIN"(W)"CONTAINING
   "(W)"PROTEIN"(W)"3")
1080 "PATATIN"
149692 "LIKE"
8785 "PHOSPHOLIPASE"
109582 "DOMAIN"
998416 "CONTAINING"
5477 "PROTEINS"
14 "PNPLA3"
1 "PATATIN-LIKE PHOSPHOLIPASE DOMAIN-CONTAINING PROTEINS, PNPLA3"
  ("PATATIN"(W)"LIKE"(W)"PHOSPHOLIPASE"(W)"DOMAIN"(W)"CONTAINING
   "(W)"PROTEINS"(W)"PNPLA3")
L2 14 "PNPLA3" OR "PNPLA3" OR "PATATIN-LIKE PHOSPHOLIPASE DOMAIN-CONTG
    . PROTEIN 3" OR "GENE PNPLA3 PROTEIN" OR "PROTEINS, PNPLA3" OR
    "PATATIN-LIKE PHOSPHOLIPASE DOMAIN-CONTAINING PROTEIN 3" OR "PAT
    ATIN-LIKE PHOSPHOLIPASE DOMAIN-CONTAINING PROTEINS, PNPLA3"

```

```

=> S "Calcium-independent phospholipase A2-epsilon" OR "Calcium-independent
phospholipase A2-.epsilon." OR "iPLA2.epsilon." OR "iPLA2-epsilon" OR
"Acyltransferase PNPLA3"

```

```

193406 "CALCIUM"
1861 "INDEPENDENT"
8785 "PHOSPHOLIPASE"
17969 "A2"
64981 "EPSILON"
1 "CALCIUM-INDEPENDENT PHOSPHOLIPASE A2-EPSILON"
  ("CALCIUM"(W)"INDEPENDENT"(W)"PHOSPHOLIPASE"(W)"A2"(W)"EPSILON
   ")
193406 "CALCIUM"
1861 "INDEPENDENT"
8785 "PHOSPHOLIPASE"
17969 "A2"
62514 "E"
1 "CALCIUM-INDEPENDENT PHOSPHOLIPASE A2-E"
  ("CALCIUM"(W)"INDEPENDENT"(W)"PHOSPHOLIPASE"(W)"A2"(W)".EPSILO
   N.")
1 "IPLA2E"
37 "IPLA2"
64981 "EPSILON"
1 "IPLA2-EPSILON"
  ("IPLA2"(W)"EPSILON")
9753 "ACYLTRANSFERASE"
14 "PNPLA3"
1 "ACYLTRANSFERASE PNPLA3"
  ("ACYLTRANSFERASE"(W)"PNPLA3")
L3 1 "CALCIUM-INDEPENDENT PHOSPHOLIPASE A2-EPSILON" OR "CALCIUM-INDEP
    ENDENT PHOSPHOLIPASE A2-E" OR "IPLA2E" OR "IPLA2
    -EPSILON" OR "ACYLTRANSFERASE PNPLA3"

```

```

=> S L2 AND L3

```

```

L4 1 L2 AND L3

```

```

=> S L2 OR L3

```

```

L5 14 L2 OR L3

```

```

=> S L1 AND L5

```

```

L6 0 L1 AND L5

```

```

=> L1 AND PNPLA3

```

```

L1 IS NOT A RECOGNIZED COMMAND

```

```

The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter

```

"HELP COMMANDS" at an arrow prompt (=>).

=> S L1 AND PNPLA3

14 PNPLA3
L7 0 L1 AND PNPLA3

=> FILE CAPLUS

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	1039.96	1040.24

FILE 'CAPLUS' ENTERED AT 15:36:23 ON 02 JUL 2023
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
COPYRIGHT (C) 2023 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications.

The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 2 Jul 2023 VOL 183 ISS 4
FILE LAST UPDATED: 30 Jun 2023 (20230630/ED)

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy>

Huge expansion of patent authority coverage in CA/Caplus provides more complete patent families, expanded invention coverage. See NEWS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> S L1 AND PNPLA3

8 L1
1275 PNPLA3
L8 3 L1 AND PNPLA3

=> S L2 OR L3

959 L2
895 L3
L9 959 L2 OR L3

=> S L1 AND L9

8 L1
L10 3 L1 AND L9

=> S L10 AND PD<20190918

51551560 PD<20190918
(PD<20190918)
L11 0 L10 AND PD<20190918

=> D 1-3 BIB ABS HITIND

L11 HAS NO ANSWERS

L1 32 SEA FILE=REGISTRY CTTTATTCAATGTGGC/SQSN
L2 14 SEA FILE=REGISTRY "PNPLA3" OR "PNPLA3" OR "PATATIN-LIKE"

PHOSPHOLIPASE DOMAIN-CONTG. PROTEIN 3" OR "GENE PNPLA3
 PROTEIN" OR "PROTEINS, PNPLA3" OR "PATATIN-LIKE PHOSPHOLIPASE
 DOMAIN-CONTAINING PROTEIN 3" OR "PATATIN-LIKE PHOSPHOLIPASE
 DOMAIN-CONTAINING PROTEINS, PNPLA3"

L3 1 SEA FILE=REGISTRY "CALCIUM-INDEPENDENT PHOSPHOLIPASE A2-EPSILON
 " OR "CALCIUM-INDEPENDENT PHOSPHOLIPASE A2-E" OR
 "IPLA2E" OR "IPLA2-EPSILON" OR "ACYLTRANSFERASE
 PNPLA3"

L9 959 SEA FILE=CAPLUS L2 OR L3

L10 3 SEA FILE=CAPLUS L1 AND L9

L11 0 SEA FILE=CAPLUS L10 AND PD<20190918

=> D L10 1-3 BIB ABS HITIND

L10 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2023 ACS on STN
[PatentPak PDF](#) | [PatentPak PDF+](#) | [PatentPak Interactive](#)

AN 2022:3093399 CAPLUS [Full-text](#)

DN 181:178899

TI Combination therapies for treatment of liver diseases

IN Linden, Daniel

PA AstraZeneca AB, Swed.

SO PCT Int. Appl., 75pp.
 CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PPPI

	PATENT NO.	KIND	DATE	LANGUAGE	PatentPak
PI	WO 2022259145	A1	20221215	English	PDF PDF+ Interactive

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PRAI	WO 2022259145	A1	20221215	WO 2022-IB55292	20220607
PSPI	US 2021-63208299	P	20210608		

	PATENT NO.	KIND	STATUS	STATUS DATE
AB	WO 2022259145	A1	Alive	20221222

Provided are methods of treating a liver disease in a subject, comprising administering to the subject: (i) an inhibitor of patatin like phospholipase domain contg. 3 (PNPLA3) expression; and (ii) an agonist of glucagon receptor and/or glucagon-like peptide-1 receptor. Also provided pharmaceutical and kits comprising (i) an inhibitor of PNPLA3 expression; and (ii) an agonist of glucagon receptor and/or GLP-1 receptor.

IPCI C12N0015-113 [I]; A61K0038-16 [I]; A61K0031-712 [I]

IPCR C12N0015-113 [I]; A61K0031-712 [I]; A61K0038-16 [I]

CC 63-1 (Pharmaceuticals)

Section cross-reference(s): 3, 6

IT 56-86-0, Glutamic acid, biological studies 71-30-7, Cytosine 554-01-8
[712321-22-7](#), PNPLA3

RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (combination therapies for treatment of liver diseases)

IT [2882148-76-5](#)

RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (combination therapies for treatment of liver diseases)

IT [2882881-85-6](#) 2882881-86-7 2882881-87-8 2882881-88-9

2882881-89-0 2882881-90-3 2882881-91-4 2882881-92-5 2882881-93-6

RL: BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(nucleotide sequence; combination therapies for treatment of liver diseases)

RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

LINK INFORMATION

PUBLICATIONS	APPLICATIONS	REGISTER
--------------	--------------	----------

L10 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2023 ACS on STN
[PatentPak PDF](#) | [PatentPak PDF+](#) | [PatentPak Interactive](#)

AN 2022:772769 CAPLUS [Full-text](#)

DN 178:216033

TI Pharmaceutical compositions comprising an antisense oligonucleotide for oral administration

IN Tivesten, Anna; Davies, Nigel; Elebring, Marie; Gennemark, Peter; Marucci, Mariagrazia; Clemmensen, Niclas; Matic, Hanna; Putra, Okky; Upadhyay, Pratik Pankaj; Walter, Katrin; Raadevik, Andreas; Tillman, Lloyd; Dellamary, Luis

PA Astrazeneca AB, Swed.; Ionis Pharmaceuticals, Inc

SO PCT Int. Appl., 64pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PPPI

PATENT NO.	KIND	DATE	LANGUAGE	PatentPak
WO 2022058465	A1	20220324	English	PDF PDF+ Interactive
CA 3191517	A1	20220324	English	PDF
KR 2023069186	A	20230518	Korean	PDF
CN 116261460	A	20230613	Chinese	PDF

PI

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2022058465	A1	20220324	WO 2021-EP75548	20210916
CA 3191517	A1	20220324	CA 2021-3191517	20210916
BR 112023004577	A2	20230411	BR 2023-112023004577	20210916
AU 2021346205	A1	20230518	AU 2021-346205	20210916
KR 2023069186	A	20230518	KR 2023-7012665	20210916
CN 116261460	A	20230613	CN 2021-80061626	20210916

PRAI

US 2020-63079941	P	20200917
US 2020-63114232	P	20201116
WO 2021-EP75548	W	20210916

PSPI

PATENT NO.	KIND	STATUS	STATUS DATE
WO 2022058465	A1	Alive	20220331
CA 3191517	A1	Alive	20230420
BR 112023004577	A2	Alive	20230420
AU 2021346205	A1	Alive	20230525
KR 2023069186	A	Alive	20230615
CN 116261460	A	Alive	20230622

OS CASFORMULTNS 2022:772769

AB A pharmaceutical compn. comprising (A) one or more ASO or a pharmaceutically acceptable salt thereof; (B) one or more permeation enhancer; (C) one or more optional pharmaceutically acceptable excipient; and (D) one or more optional coating. Said compn. for use in the treatment, prevention, or amelioration of a disease assocd. with PCSK9 or PNPLA3 in a subject.

IPCI A61P0001-16 [I]; A61P0009-10 [I]; A61K0031-711 [I]; A61K0009-20 [I]; A61K0038-48 [I]

IPCR A61P0001-16 [I]; A61K0009-20 [I]; A61K0031-711 [I]; A61K0038-48 [I]; A61P0009-10 [I]

CC 63-6 (Pharmaceuticals)

IT 2765706-01-0P, ION 863633 2765706-02-1P, ION 863633 sodium salt **2765706-03-2P**, ION 975616 sodium salt **2765706-04-3P**, ION 975616

RL: BPN (Biosynthetic preparation); PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (pharmaceutical compns. comprising antisense oligonucleotide for oral administration)

IT **712321-22-7**, PNPLA3 778625-08-4, PCSK9

RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (pharmaceutical compns. comprising antisense oligonucleotide for oral administration)

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

LINK INFORMATION

PUBLICATIONS	APPLICATIONS	REGISTER
AU 2021346205 A1	AU 2021-346205	Register
BR 112023004577 A2	BR 2023-112023004577	Register
CA 3191517 A1	CA 2021-3191517	Register
CN 116261460 A	CN 2021-80061626	Register Global Dossier
KR 2023069186 A	KR 2023-7012665	Register Global Dossier
WO 2022058465 A1	WO 2021-EP75548	Register Global Dossier

L10 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2023 ACS on STN

[PatentPak PDF](#) | [PatentPak PDF+](#) | [PatentPak Interactive](#)AN 2021:920025 CAPLUS [Full-text](#)

DN 174:901676

TI Oligonucleotide modulators of patatin like phospholipase domain containing 3 PNPLA3 gene expression for treating diseases such as liver disease

IN Linden, Daniel

PA AstraZeneca AB, Swed.

SO PCT Int. Appl., 255pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PPPI

PATENT NO.	KIND	DATE	LANGUAGE	PatentPak
WO 2021074772	A1	20210422	English	PDF PDF+ Interactive
CN 114728017	A	20220708	Chinese	PDF

PI

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2021074772	A1	20210422	WO 2020-IB59566	20201012
CN 114728017	A	20220708	CN 2020-80071323	20201012
EP 4045062	A1	20220824	EP 2020-793825	20201012
JP 2022552249	T	20221215	JP 2022-521139	20201012

PRAI US 2019-62914660

WO 2020-IB59566

PSPI

PATENT NO.	KIND	STATUS	STATUS DATE
WO 2021074772	A1	Alive	20210506
CN 114728017	A	Alive	20220714
EP 4045062	A1	Alive	20220825

AB The present embodiments provide methods, compds., and compns. useful for inhibiting patatin-like phospholipase domain contg. 3 (adiponutrin) PNPLA3 gene expression, which may be useful for treating, preventing, or ameliorating a disease assocd. with PNPLA3. In some embodiments, the methods, compds., and compns. are useful for treating, preventing, or ameliorating a disease assocd. with PNPLA3 having an 1148M mutation. In some embodiments, the present disclosure provides a method of treating an individual having or at risk of having liver disease. In some embodiments, the compd. targeted to PNPLA3, in an individual having an 1148M mutation, comprises a modified oligonucleotide 8 to 80 linked nucleosides in length having a nucleobase sequence.

IPCI A61K0031-713 [I]; C12N0015-00 [I]

IPCR A61K0031-713 [I]; C12N0015-00 [I]

CC 1-12 (Pharmacology)

IT	2640433-44-7	2640433-45-8	2640433-46-9	2640433-47-0	2640433-48-1
	2640433-49-2	2640433-50-5	2640433-51-6	2640433-52-7	2640433-53-8
	2640433-54-9	2640433-55-0	2640433-56-1	2640433-57-2	2640433-58-3
	2640433-59-4	2640433-60-7	2640433-61-8	2640433-62-9	2640433-63-0
	2640433-64-1	2640433-65-2	2640433-66-3	2640433-67-4	2640433-68-5
	2640433-69-6	2640433-70-9	2640433-71-0	2640433-72-1	2640433-73-2
	2640433-74-3	2640433-75-4	2640433-76-5	2640433-77-6	2640433-78-7
	2640433-79-8	2640433-80-1	2640433-81-2	2640433-82-3	2640433-83-4
	2640433-84-5	2640433-85-6	2640433-86-7	2640433-87-8	2640433-88-9
	2640433-89-0	2640433-90-3	2640433-91-4	2640433-92-5	2640433-93-6
	2640433-94-7	2640433-95-8	2640433-96-9	2640433-97-0	2640433-98-1
	2640433-99-2	2640434-00-8	2640434-01-9	2640434-02-0	2640434-03-1
	2640434-04-2	2640434-05-3	2640434-06-4	2640434-07-5	2640434-08-6
	2640434-09-7	2640434-10-0	2640434-11-1	2640434-12-2	2640434-13-3

2640434-14-4	2640434-15-5	2640434-16-6	2640434-17-7	2640434-18-8
2640434-19-9	2640434-20-2	2640434-21-3	2640434-22-4	2640434-23-5
2640434-24-6	2640434-25-7	2640434-26-8	2640434-27-9	2640434-28-0
2640434-29-1	2640434-30-4	2640434-31-5	2640434-32-6	2640434-33-7
2640434-34-8	2640434-35-9	2640434-36-0	2640434-37-1	2640434-38-2
2640434-39-3	2640434-40-6	2640434-41-7	2640434-42-8	2640434-43-9
2640434-44-0	2640434-45-1	2640434-46-2	2640434-47-3	2640434-48-4
2640434-49-5	2640434-50-8	2640434-51-9	2640434-52-0	2640434-53-1
2640434-54-2	2640434-55-3	2640434-56-4	2640434-57-5	2640434-58-6
2640434-59-7	2640434-60-0	2640434-61-1	2640434-62-2	2640434-63-3
2640434-64-4	2640434-65-5	2640434-66-6	2640434-67-7	2640434-68-8
2640434-69-9	2640434-70-2	2640434-71-3	2640434-72-4	
2640434-73-5	2640434-74-6	2640434-75-7	2640434-76-8	2640434-77-9
2640434-78-0	2640434-79-1	2640434-80-4	2640434-81-5	2640434-82-6
2640434-83-7	2640434-84-8	2640434-85-9	2640434-86-0	2640434-87-1
2640434-88-2	2640434-89-3	2640434-90-6	2640434-91-7	2640434-92-8
2640434-93-9	2640434-94-0	2640434-95-1	2640434-96-2	2640434-97-3
2640434-98-4	2640434-99-5	2640435-00-1	2640435-01-2	2640435-02-3
2640435-03-4	2640435-04-5	2640435-05-6	2640435-06-7	2640435-07-8
2640435-08-9	2640435-09-0	2640435-10-3	2640435-11-4	2640435-12-5
2640435-13-6	2640435-14-7	2640435-15-8	2640435-16-9	2640435-17-0
2640435-18-1	2640435-19-2	2640435-20-5	2640435-21-6	2640435-22-7
2640435-23-8	2640435-24-9	2640435-25-0	2640435-26-1	2640435-27-2
2640435-28-3	2640435-29-4	2640435-30-7	2640435-31-8	2640435-32-9
2640435-33-0	2640435-34-1	2640435-35-2	2640435-36-3	2640435-37-4
2640435-38-5	2640435-39-6	2640435-40-9	2640435-41-0	2640435-42-1
2640435-43-2	2640435-44-3	2640435-45-4	2640435-46-5	2640435-47-6
2640435-48-7	2640435-49-8	2640435-50-1	2640435-51-2	2640435-52-3
2640435-53-4	2640435-54-5	2640435-55-6	2640435-56-7	2640435-57-8
2640435-58-9	2640435-59-0	2640435-60-3	2640435-61-4	2640435-62-5
2640435-63-6	2640435-64-7	2640435-65-8	2640435-66-9	2640435-67-0
2640435-68-1	2640435-69-2	2640435-70-5	2640435-71-6	2640435-72-7
2640435-73-8	2640435-74-9	2640435-75-0	2640435-76-1	2640435-77-2

RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(nucleotide sequence, PNPLA3-targeted antisense oligonucleotide; oligonucleotide modulators of patatin like phospholipase domain contg. 3 PNPLA3 gene expression for treating diseases such as liver disease)

IT **712321-22-7**, Patatin-like phospholipase domain-containing protein 3

RL: ANT (Analyte); PAC (Pharmacological activity); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)

(oligonucleotide modulators of patatin like phospholipase domain contg. 3 PNPLA3 gene expression for treating diseases such as liver disease)

IT	1811-31-0D, GalNAc, conjugates with PNPLA3-targeted antisense oligonucleotides	2640618-25-1	2640618-26-2	2640698-24-2
		2640698-25-3	2640698-26-4	2640698-27-5
		2640698-30-0	2640698-31-1	2640698-32-2
		2640802-04-4	2640802-05-5	2640802-06-6
		2640802-08-8	2640802-09-9	2640802-10-2
		2640802-11-3	2640802-12-4	2640802-13-5
		2640802-15-7	2640802-16-8	2640802-17-9
		2640802-20-4	2640802-21-5	2640802-22-6
		2640802-25-9	2640802-26-0	2640802-27-1
		2640802-29-3	2640802-30-6	2640802-31-7
		2640802-34-0	2640802-35-1	2640802-36-2
		2640802-39-5	2640812-36-6	2640802-37-3
				2640802-38-4

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(oligonucleotide modulators of patatin like phospholipase domain contg. 3 PNPLA3 gene expression for treating diseases such as liver disease)

OSC.G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

LINK INFORMATION

PUBLICATIONS	APPLICATIONS	REGISTER
CN 114728017 A	CN 2020-80071323	Register Global Dossier
EP 4045062 A1	EP 2020-793825	Register Federated Req.
JP 2022552249 T	JP 2022-521139	Register Global Dossier
WO 2021074772 A1	WO 2020-IB59566	Register Global Dossier

=> S UUUUAUCAAUGUGGC/SQSN

REG1stRY INITIATED

Substance data SEARCH and crossover from CAS REGISTRY in progress...
Use DISPLAY HITSTR (or FHITSTR) to directly view retrieved structures.

L13 45 L12

=> S L13 AND L9

L14 3 L13 AND L9

=> D L14 1-3 BIB ABS HITIND

L14 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2023 ACS on STN
[PatentPak PDF](#) | [PatentPak PDF+](#) | [PatentPak Interactive](#)

AN 2022:3093399 CAPLUS [Full-text](#)

DN 181:178899

TI Combination therapies for treatment of liver diseases

IN Linden, Daniel

PA AstraZeneca AB, Swed.

SO PCT Int. Appl., 75pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PPPI

PATENT NO.	KIND	DATE	LANGUAGE	PatentPak
WO 2022259145	A1	20221215	English	PDF PDF+ Interactive

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2022259145	A1	20221215	WO 2022-IB55292	20220607
PRAI US 2021-63208299	P	20210608		

PSPI

PATENT NO.	KIND	STATUS	STATUS DATE
WO 2022259145	A1	Alive	20221222

AB Provided are methods of treating a liver disease in a subject, comprising administering to the subject: (i) an inhibitor of patatin like phospholipase domain contg. 3 (PNPLA3) expression; and (ii) an agonist of glucagon receptor and/or glucagon-like peptide-1 receptor. Also provided pharmaceutical and kits comprising (i) an inhibitor of PNPLA3 expression; and (ii) an agonist of glucagon receptor and/or GLP-1 receptor.

IPCI C12N0015-113 [I]; A61K0038-16 [I]; A61K0031-712 [I]

IPCR C12N0015-113 [I]; A61K0031-712 [I]; A61K0038-16 [I]

CC 63-1 (Pharmaceuticals)

Section cross-reference(s): 3, 6

IT 56-86-0, Glutamic acid, biological studies 71-30-7, Cytosine 554-01-8
[712321-22-7](#), PNPLA3

RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(combination therapies for treatment of liver diseases)

IT [2882148-76-5](#)

RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(combination therapies for treatment of liver diseases)

IT [2882881-85-6](#) 2882881-86-7 2882881-87-8 2882881-88-9

2882881-89-0 2882881-90-3 2882881-91-4 2882881-92-5 2882881-93-6
RL: BSU (Biological study, unclassified); PRP (Properties); THU
(Therapeutic use); BIOL (Biological study); USES (Uses)
(nucleotide sequence; combination therapies for treatment of liver
diseases)

RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

LINK INFORMATION

PUBLICATIONS	APPLICATIONS	REGISTER
WO 2022259145 A1	WO 2022-IB55292	Register Global Dossier

L14 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2023 ACS on STN
[PatentPak PDF](#) | [PatentPak PDF+](#) | [PatentPak Interactive](#)

AN 2022:772769 CAPLUS [Full-text](#)

DN 178:216033

TI Pharmaceutical compositions comprising an antisense oligonucleotide for
oral administration

IN Tivesten, Anna; Davies, Nigel; Elebring, Marie; Gennemark, Peter; Marucci,
Mariagrazia; Clemmensen, Niclas; Matic, Hanna; Putra, Okky; Upadhyay,
Pratik Pankaj; Walter, Katrin; Raadevik, Andreas; Tillman, Lloyd;
Dellamary, Luis

PA Astrazeneca AB, Swed.; Ionis Pharmaceuticals, Inc

SO PCT Int. Appl., 64pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PPPI

PATENT NO.	KIND	DATE	LANGUAGE	PatentPak
WO 2022058465	A1	20220324	English	PDF PDF+ Interactive
CA 3191517	A1	20220324	English	PDF
KR 2023069186	A	20230518	Korean	PDF
CN 116261460	A	20230613	Chinese	PDF

PI

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2022058465	A1	20220324	WO 2021-EP75548	20210916
CA 3191517	A1	20220324	CA 2021-3191517	20210916
BR 112023004577	A2	20230411	BR 2023-112023004577	20210916
AU 2021346205	A1	20230518	AU 2021-346205	20210916
KR 2023069186	A	20230518	KR 2023-7012665	20210916
CN 116261460	A	20230613	CN 2021-80061626	20210916

PRAI US 2020-63079941

US 2020-63114232

WO 2021-EP75548

PSPI

PATENT NO.	KIND	STATUS	STATUS DATE
WO 2022058465	A1	Alive	20220331
CA 3191517	A1	Alive	20230420
BR 112023004577	A2	Alive	20230420
AU 2021346205	A1	Alive	20230525
KR 2023069186	A	Alive	20230615
CN 116261460	A	Alive	20230622

OS CASFORMULTNS 2022:772769

AB A pharmaceutical compn. comprising (A) one or more ASO or a
pharmaceutically acceptable salt thereof; (B) one or more permeation
enhancer; (C) one or more optional pharmaceutically acceptable excipient;
and (D) one or more optional coating. Said compn. for use in the
treatment, prevention, or amelioration of a disease assocd. with PCSK9 or
PNPLA3 in a subject.

IPCI A61P0001-16 [I]; A61P0009-10 [I]; A61K0031-711 [I]; A61K0009-20 [I];
A61K0038-48 [I]

IPCR A61P0001-16 [I]; A61K0009-20 [I]; A61K0031-711 [I]; A61K0038-48 [I];
A61P0009-10 [I]

CC 63-6 (Pharmaceuticals)

IT 2765706-01-OP, ION 863633 2765706-02-1P, ION 863633 sodium salt
[2765706-03-2P](#), ION 975616 sodium salt [2765706-04-3P](#),
ION 975616

RL: BPN (Biosynthetic preparation); PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(pharmaceutical compns. comprising antisense oligonucleotide for oral administration)

IT **712321-22-7**, PNPLA3 778625-08-4, PCSK9

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(pharmaceutical compns. comprising antisense oligonucleotide for oral administration)

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

LINK INFORMATION

PUBLICATIONS	APPLICATIONS	REGISTER
AU 2021346205 A1	AU 2021-346205	Register
BR 112023004577 A2	BR 2023-112023004577	Register
CA 3191517 A1	CA 2021-3191517	Register
CN 116261460 A	CN 2021-80061626	Register Global Dossier
KR 2023069186 A	KR 2023-7012665	Register Global Dossier
WO 2022058465 A1	WO 2021-EP75548	Register Global Dossier

L14 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2023 ACS on STN
[PatentPak PDF](#) | [PatentPak PDF+](#) | [PatentPak Interactive](#)

AN 2021:920025 CAPLUS [Full-text](#)

DN 174:901676

TI Oligonucleotide modulators of patatin like phospholipase domain containing 3 PNPLA3 gene expression for treating diseases such as liver disease

IN Linden, Daniel

PA AstraZeneca AB, Swed.

SO PCT Int. Appl., 255pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PPPI

PATENT NO.	KIND	DATE	LANGUAGE	PatentPak
WO 2021074772	A1	20210422	English	PDF PDF+ Interactive
CN 114728017	A	20220708	Chinese	PDF

PI

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2021074772	A1	20210422	WO 2020-IB59566	20201012
CN 114728017	A	20220708	CN 2020-80071323	20201012
EP 4045062	A1	20220824	EP 2020-793825	20201012
JP 2022552249	T	20221215	JP 2022-521139	20201012

PRAI US 2019-62914660

WO 2020-IB59566 W 20201012

PSPI

PATENT NO.	KIND	STATUS	STATUS DATE
WO 2021074772	A1	Alive	20210506
CN 114728017	A	Alive	20220714
EP 4045062	A1	Alive	20220825

AB The present embodiments provide methods, compds., and compns. useful for inhibiting patatin-like phospholipase domain contg. 3 (adiponutrin) PNPLA3 gene expression, which may be useful for treating, preventing, or ameliorating a disease assocd. with PNPLA3. In some embodiments, the methods, compds., and compns. are useful for treating, preventing, or ameliorating a disease assocd. with PNPLA3 having an 1148M mutation. In some embodiments, the present disclosure provides a method of treating an individual having or at risk of having liver disease. In some embodiments, the compd. targeted to PNPLA3, in an individual having an 1148M mutation, comprises a modified oligonucleotide 8 to 80 linked nucleosides in length having a nucleobase sequence.

IPCI A61K0031-713 [I]; C12N0015-00 [I]

IPCR A61K0031-713 [I]; C12N0015-00 [I]

CC 1-12 (Pharmacology)

IT 2640433-44-7 2640433-45-8 2640433-46-9 2640433-47-0 2640433-48-1
2640433-49-2 2640433-50-5 2640433-51-6 2640433-52-7 2640433-53-8
2640433-54-9 2640433-55-0 2640433-56-1 2640433-57-2 2640433-58-3

2640433-59-4	2640433-60-7	2640433-61-8	2640433-62-9	2640433-63-0
2640433-64-1	2640433-65-2	2640433-66-3	2640433-67-4	2640433-68-5
2640433-69-6	2640433-70-9	2640433-71-0	2640433-72-1	2640433-73-2
2640433-74-3	2640433-75-4	2640433-76-5	2640433-77-6	2640433-78-7
2640433-79-8	2640433-80-1	2640433-81-2	2640433-82-3	2640433-83-4
2640433-84-5	2640433-85-6	2640433-86-7	2640433-87-8	2640433-88-9
2640433-89-0	2640433-90-3	2640433-91-4	2640433-92-5	2640433-93-6
2640433-94-7	2640433-95-8	2640433-96-9	2640433-97-0	2640433-98-1
2640433-99-2	2640434-00-8	2640434-01-9	2640434-02-0	2640434-03-1
2640434-04-2	2640434-05-3	2640434-06-4	2640434-07-5	2640434-08-6
2640434-09-7	2640434-10-0	2640434-11-1	2640434-12-2	2640434-13-3
2640434-14-4	2640434-15-5	2640434-16-6	2640434-17-7	2640434-18-8
2640434-19-9	2640434-20-2	2640434-21-3	2640434-22-4	2640434-23-5
2640434-24-6	2640434-25-7	2640434-26-8	2640434-27-9	2640434-28-0
2640434-29-1	2640434-30-4	2640434-31-5	2640434-32-6	2640434-33-7
2640434-34-8	2640434-35-9	2640434-36-0	2640434-37-1	2640434-38-2
2640434-39-3	2640434-40-6	2640434-41-7	2640434-42-8	2640434-43-9
2640434-44-0	2640434-45-1	2640434-46-2	2640434-47-3	2640434-48-4
2640434-49-5	2640434-50-8	2640434-51-9	2640434-52-0	2640434-53-1
2640434-54-2	2640434-55-3	2640434-56-4	2640434-57-5	2640434-58-6
2640434-59-7	2640434-60-0	2640434-61-1	2640434-62-2	2640434-63-3
2640434-64-4	2640434-65-5	2640434-66-6	2640434-67-7	2640434-68-8
2640434-69-9	2640434-70-2	2640434-71-3	2640434-72-4	
2640434-73-5	2640434-74-6	2640434-75-7	2640434-76-8	2640434-77-9
2640434-78-0	2640434-79-1	2640434-80-4	2640434-81-5	2640434-82-6
2640434-83-7	2640434-84-8	2640434-85-9	2640434-86-0	2640434-87-1
2640434-88-2	2640434-89-3	2640434-90-6	2640434-91-7	2640434-92-8
2640434-93-9	2640434-94-0	2640434-95-1	2640434-96-2	2640434-97-3
2640434-98-4	2640434-99-5	2640435-00-1	2640435-01-2	2640435-02-3
2640435-03-4	2640435-04-5	2640435-05-6	2640435-06-7	2640435-07-8
2640435-08-9	2640435-09-0	2640435-10-3	2640435-11-4	2640435-12-5
2640435-13-6	2640435-14-7	2640435-15-8	2640435-16-9	2640435-17-0
2640435-18-1	2640435-19-2	2640435-20-5	2640435-21-6	2640435-22-7
2640435-23-8	2640435-24-9	2640435-25-0	2640435-26-1	2640435-27-2
2640435-28-3	2640435-29-4	2640435-30-7	2640435-31-8	2640435-32-9
2640435-33-0	2640435-34-1	2640435-35-2	2640435-36-3	2640435-37-4
2640435-38-5	2640435-39-6	2640435-40-9	2640435-41-0	2640435-42-1
2640435-43-2	2640435-44-3	2640435-45-4	2640435-46-5	2640435-47-6
2640435-48-7	2640435-49-8	2640435-50-1	2640435-51-2	2640435-52-3
2640435-53-4	2640435-54-5	2640435-55-6	2640435-56-7	2640435-57-8
2640435-58-9	2640435-59-0	2640435-60-3	2640435-61-4	2640435-62-5
2640435-63-6	2640435-64-7	2640435-65-8	2640435-66-9	2640435-67-0
2640435-68-1	2640435-69-2	2640435-70-5	2640435-71-6	2640435-72-7
2640435-73-8	2640435-74-9	2640435-75-0	2640435-76-1	2640435-77-2

RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(nucleotide sequence, PNPLA3-targeted antisense oligonucleotide;
oligonucleotide modulators of patatin like phospholipase domain contg.
3 PNPLA3 gene expression for treating diseases such as liver disease)

IT	2640440-48-6	2640440-49-7	2640440-50-0	2640440-51-1	2640440-52-2
	2640440-53-3	2640440-54-4	2640440-55-5	2640440-56-6	2640440-57-7
	2640440-58-8	2640440-59-9	2640440-60-2	2640440-61-3	2640440-62-4
	2640440-63-5	2640440-64-6	2640440-65-7	2640440-66-8	2640440-67-9
	2640440-68-0	2640440-69-1	2640440-70-4	2640440-71-5	2640440-72-6
	2640440-73-7	2640440-74-8	2640440-75-9	2640440-76-0	2640440-77-1
	2640440-78-2	2640440-79-3	2640440-80-6	2640440-81-7	2640440-82-8
	2640440-83-9	2640440-84-0	2640440-85-1	2640440-86-2	2640440-87-3
	2640440-88-4	2640440-89-5	2640440-90-8	2640440-91-9	2640440-92-0
	2640440-93-1	2640440-94-2	2640440-95-3	2640440-96-4	2640440-97-5
	2640440-98-6	2640440-99-7	2640441-00-3	2640441-01-4	2640441-02-5
	2640441-03-6	2640441-04-7	2640441-05-8	2640441-06-9	2640441-07-0
	2640441-08-1	2640441-09-2	2640441-10-5	2640441-11-6	2640441-12-7
	2640441-13-8	2640441-14-9	2640441-15-0	2640441-16-1	2640441-17-2
	2640441-18-3	2640441-19-4	2640441-20-7	2640441-21-8	2640441-22-9
	2640441-23-0	2640441-24-1	2640441-25-2	2640441-26-3	2640441-27-4
	2640441-28-5	2640441-29-6	2640441-30-9	2640441-31-0	2640441-32-1
	2640441-33-2	2640441-34-3	2640441-35-4	2640441-36-5	2640441-37-6
	2640441-38-7	2640441-39-8	2640441-40-1	2640441-41-2	2640441-42-3
	2640441-43-4	2640441-44-5	2640441-45-6	2640441-46-7	
	2640441-47-8	2640441-48-9	2640441-49-0	2640441-50-3	
	2640441-51-4	2640441-52-5	2640441-53-6	2640441-54-7	2640441-55-8
	2640441-56-9	2640441-57-0	2640441-58-1	2640441-59-2	2640441-60-5

	2640441-61-6	2640441-62-7	2640441-63-8	2640441-64-9	2640441-65-0
	2640441-66-1	2640441-67-2	2640441-68-3	2640441-69-4	2640441-70-7
	2640441-71-8	2640441-72-9	2640441-73-0	2640441-74-1	2640441-75-2
	2640441-76-3	2640441-77-4	2640441-78-5	2640441-79-6	2640441-80-9
	2640441-81-0	2640441-82-1	2640441-83-2	2640441-84-3	2640441-85-4
	2640441-86-5	2640441-88-7	2640441-89-8	2640441-90-1	2640441-91-2
	2640441-92-3	2640441-93-4	2640441-94-5	2640441-95-6	2640441-96-7
	2640441-97-8	2640441-98-9	2640441-99-0	2640442-00-6	2640442-01-7
	2640442-02-8	2640442-03-9	2640442-04-0	2640442-05-1	2640442-06-2
	2640442-07-3	2640442-08-4	2640442-09-5	2640442-10-8	2640442-11-9
	2640442-12-0	2640442-13-1	2640442-14-2	2640442-15-3	2640442-16-4
	2640442-17-5	2640442-18-6	2640442-19-7	2640442-20-0	2640442-21-1
	2640442-22-2	2640442-23-3	2640442-24-4	2640442-25-5	2640442-26-6
	2640442-27-7	2640442-28-8	2640442-29-9	2640442-30-2	2640442-31-3
	2640442-32-4	2640442-33-5	2640442-34-6	2640442-35-7	2640442-36-8
	2640442-37-9	2640442-38-0	2640442-39-1	2640442-40-4	2640442-41-5
	2640442-42-6	2640442-43-7	2640442-44-8	2640442-45-9	2640442-46-0
	2640442-47-1	2640442-48-2	2640442-49-3	2640442-50-6	2640442-51-7
	2640442-52-8	2640442-53-9	2640442-54-0	2640442-55-1	2640442-56-2
	2640442-57-3	2640442-58-4	2640442-59-5	2640442-60-8	2640442-61-9
	2640442-62-0	2640442-63-1	2640442-64-2	2640442-65-3	2640442-66-4
	2640442-67-5	2640442-68-6	2640442-69-7	2640442-70-0	2640442-71-1
	2640442-72-2	2640442-73-3	2640442-74-4	2640442-75-5	2640442-76-6
	2640442-77-7	2640442-78-8	2640442-79-9	2640442-80-2	2640442-81-3
	2640442-82-4				

RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(nucleotide sequence, PNPLA3-targeted antisense oligonucleotide;
oligonucleotide modulators of patatin like phospholipase domain contg.
3 PNPLA3 gene expression for treating diseases such as liver disease)

IT **712321-22-7**, Patatin-like phospholipase domain-containing protein 3
RL: ANT (Analyte); PAC (Pharmacological activity); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(oligonucleotide modulators of patatin like phospholipase domain contg.
3 PNPLA3 gene expression for treating diseases such as liver disease)

IT 1811-31-0D, GalNAc, conjugates with PNPLA3-targeted antisense oligonucleotides 2640618-25-1 2640618-26-2 2640698-24-2
2640698-25-3 2640698-26-4 2640698-27-5 2640698-28-6 2640698-29-7
2640698-30-0 2640698-31-1 2640698-32-2 **2640698-33-3**
2640802-03-3 **2640802-04-4** **2640802-05-5**
2640802-06-6 **2640802-07-7** **2640802-08-8**
2640802-09-9 **2640802-10-2** **2640802-11-3**
2640802-12-4 2640802-13-5 2640802-14-6 2640802-15-7 2640802-16-8
2640802-17-9 2640802-18-0 2640802-19-1 2640802-20-4 2640802-21-5
2640802-22-6 2640802-23-7 2640802-24-8 2640802-25-9
2640802-26-0 2640802-27-1 2640802-28-2 2640802-29-3
2640802-30-6 2640802-31-7 2640802-32-8 2640802-33-9 2640802-34-0
2640802-35-1 2640802-36-2 2640802-37-3 2640802-38-4 2640802-39-5
2640812-36-6
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(oligonucleotide modulators of patatin like phospholipase domain contg.
3 PNPLA3 gene expression for treating diseases such as liver disease)

OSC.G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

LINK INFORMATION

PUBLICATIONS	APPLICATIONS	REGISTER
CN 114728017 A	CN 2020-80071323	Register Global Dossier
EP 4045062 A1	EP 2020-793825	Register Federated Req.
JP 2022552249 T	JP 2022-521139	Register Global Dossier
WO 2021074772 A1	WO 2020-1B59566	Register Global Dossier

=>